We focus on developing therapies against targets where existing preclinical and early clinical data is available. This data can give a strong indication that a therapy will disrupt a targeted biochemical process and improve patient outcome without significant side-effects. Sareum’s approach is lower risk than developing therapies against entirely novel targets.
We currently have two programmes in preclinical development:
Both programmes are being progressed in collaboration with co-development partners
Click here for our latest research update